Back
Summit Therapeutics 10K Form
Buy
85
SMMT
Summit Therapeutics
Last Price:
26.20
Seasonality Move:
26.72%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-11-07 | 10Q | SMMT/Summit Therapeutics Quarterly |
| 2023-08-09 | 10Q | SMMT/Summit Therapeutics Quarterly |
| 2023-05-11 | 10Q | SMMT/Summit Therapeutics Quarterly |
| 2022-11-09 | 10Q | SMMT/Summit Therapeutics Quarterly |
| 2022-08-11 | 10Q | SMMT/Summit Therapeutics Quarterly |
| 2022-05-11 | 10Q | SMMT/Summit Therapeutics Quarterly |
Receive SMMT News And Ratings
See the #1 stock for the next 7 days that we like better than SMMT
SMMT Financial Statistics
Sales & Book Value
| Annual Sales: | $705K |
|---|---|
| Cash Flow: | $-33.07M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $0.27 |
| Price / Book: | 111.06 |
Profitability
| EPS (TTM): | -0.19000 |
|---|---|
| Net Income (TTM): | $-161.69M |
| Gross Margin: | $760K |
| Return on Equity: | 0% |
| Return on Assets: | 0% |
Summit Therapeutics Earnings Forecast
Key Summit Therapeutics Financial Ratios
- The Gross Profit Margin over the past 15 years for SMMT is 102.29%.
- The Selling, General & Administrative Expenses for SMMT have been equal to 3,787.23% of Gross Profit Margin.
- The Interest Expense is -2.68% of Operating Income.
- Per Share Earnings over the last 19 years have been positive in 8 years.
Summit Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | SMMT |
| CUSIP: | 86627R |
| Website: | smmttx.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 0 |
| Quick Ratio: | 0 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
SMMT Technical Analysis vs Fundamental Analysis
Buy
85
Summit Therapeutics (SMMT)
is a Buy
Is Summit Therapeutics a Buy or a Sell?
-
Summit Therapeutics stock is rated a Buy
The current Summit Therapeutics [SMMT] share price is $29.48. The Score for SMMT is 85, which is 70% above its historic median score of 50, and infers lower risk than normal.